Jeffrey Jonas, MD

Open-Label, Phase 2 Trial of the Oral Neuroactive Steroid GABAA Receptor Positive Allosteric Modulator Zuranolone in Bipolar Disorder I and II

Background: Bipolar disorder (BPD) is a chronic, episodic illness affecting nearly 50 million globally, with disability mostly due to depressive episodes (MDEs). Zuranolone is an investig...

Handan Gunduz-Bruce , MD, MBA;

Abdul Sankoh , PhD;

Jeffrey Jonas , MD;

Indrani Nandy , PhD;

James Doherty , PhD;

Stephen Kanes , MD, PhD;

Robert Lasser , MD, MBA;

10/08/2020

Number Needed to Treat Analysis of the SAGE-217 Phase 2 Clinical Trial Results in Major Depressive Disorder

Background: SAGE-217 is a novel, positive allosteric modulator of GABA(A) receptors under development in Major Depressive Disorder (MDD). This analysis quantified the number needed to tre...

Ken O'Day , PhD, MPA;

Vijayveer Bonthapally , PhD;

Alix Arnaud , MSc;

Ellison Suthoff , MBA, BS ;

Katie Stenson , MSc;

Brian Werneburg , PhD;

Paul Hodgkins , PhD, MSc;

Jeffrey Jonas , MD;

Kellie Meyer , PharmD, MPH;

11/22/2019